Search results for "Clinical knowledge"

showing 2 items of 2 documents

Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

2017

Abstract Hepatitis C virus (HCV) infection remains one of the main causes of chronic liver disease worldwide. The advent of direct-acting antivirals (DAAs) has significantly improved the course of patients with chronic HCV infection (CHC), due to the ability of these drugs to achieve high rates of sustained virological response (SVR). These exceedingly high rates of SVR and the excellent safety data have been confirmed in real life practice. Evolving guidelines have been issued by national and international scientific societies in accordance with the progression of clinical knowledge and the availability of new DAAs. These recommendations, however, may not be applied universally because of …

Liver CirrhosisDirect-acting antiviral agentFibrosiHepacivirusChronic liver diseasemedicine.disease_causeClinical knowledgeVirological response0302 clinical medicine80 and over030212 general & internal medicineChronicAntiviral treatment; Cirrhosis; Direct-acting antiviral agents; Hepatitis C; RAV; Treatment failureAged 80 and overGastroenterologyAntiviral treatment; Cirrhosis; Direct-acting antiviral agents; Hepatitis C; RAV; Treatment failure; Hepatology; GastroenterologyHepatitis CMiddle AgedViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CCirrhosisItalyLiverCombination030211 gastroenterology & hepatologyDrug Therapy CombinationHumanAdultmedicine.medical_specialtyConsensusHepatitis C virusLiver CirrhosiConsensuAntiviral AgentsUnmet needs03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansIntensive care medicineAgedAntiviral AgentHepaciviruCirrhosiHepatologybusiness.industryHepatologyHepatitis C Chronicmedicine.diseaseVirologyFibrosisAntiviral treatmentTreatment failurePosition paperAntiviral treatment; Cirrhosis; Direct-acting antiviral agents; Hepatitis C; RAV; Treatment failure; Adult; Aged; Aged 80 and over; Antiviral Agents; Consensus; Drug Therapy Combination; Fibrosis; Hepacivirus; Hepatitis C Chronic; Humans; Italy; Liver; Liver Cirrhosis; Middle Aged; Viral Load; Young AdultDirect-acting antiviral agentsRAVbusiness
researchProduct

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?

2012

Mantle Cell Lymphoma (MCL) is associated with a dismal prognosis. Recently, along with the improved understanding of the pathophysiology of this disease, new first line regimens have been established and in addition novel treatment options have entered the clinical arena. In consequence, prognosis of the disease has fortunately improved. We here focus on the rationale, current clinical knowledge and future concepts of Temsirolimus, an inhibitor of mTOR, in the treatment of MCL. At this time this drug has been shown to be effective as single agent for relapsed disease and early combination data show promising results. In addition, with a brief outline of other treatment options, we aim to g…

Oncologymedicine.medical_specialtybusiness.industryFirst linemantle cell lymphomaCancerTreatment optionsmTOR-inhibitorReviewDiseasemedicine.diseaseBioinformaticslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282TemsirolimusClinical knowledgeOncologyInternal medicinetemsirolimusmedicineRefractory Mantle Cell LymphomaMantle cell lymphomabusinessmedicine.drugClinical Medicine Insights: Oncology
researchProduct